From: The role of lipids in corneal diseases and dystrophies: a systematic review
Disease | Lipid therapeutics/biomarkers |
---|---|
Dry eye disease [17] | Eicosapentaenoic acid, docosahexaenoic acid, and alpha linolenic acid, and resolvins have shown promise in improving symptoms of DED, matrix metalloproteinase-9 as an ideal biomarker due to its involvement in ocular surface inflammation |
Diabetic neuropathy | Menhaden oil, daily injections of resolvin-D1, salsalate, enalapril, neuroprotectin D1, docosahexaenoic acid, as well as combination of enalapril, α-lipoic acid and menhaden oil have all shown to improve diabetic neuropathy |
Fuchs’ endothelial corneal dystrophy | Mefenamic acid and nimesulide have shown to improve oxidative stress, ROCK inhibitor show potential for regenerative medicine, Diacylglycerophosphocholines, 1-ether, 2-acylglycerophosphocholines, eight sphingomyelins, and up to two long-chain highly unsaturated cholesteryl esters increased in the AH of FECD eyes, indicating potential oxidative stress markers |